中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 11
Nov.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(11): 2553-2556

Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus

DOI: 10.3969/j.issn.1001-5256.2020.11.035

  • Department of Infectious Diseases,Peking University First Hospital

Research funding:

 

  • Received Date: 2020-04-28
  • Published Date: 2020-11-20
    Abstract

  • Since the development of direct-acting antivirals( DAAs) for hepatitis C virus( HCV),more than 95% of the patients with hepatitis C can be cured,but a very small proportion of patients still face treatment failure. There are many reasons for treatment failure,among which HCV genotype and resistance-associated substitutions( RASs) in virus genes show a certain impact. This article mainly introduces the RASs associated with the NS5 B and NS5 A gene fragments in genotype 2/3 HCV,summarizes the distribution of RASs,and compares the difference in the distribution of RASs between previously untreated chronic hepatitis C patients and patients with treatment failure.

     

    • FullText(HTML)
    • References(35)
  • [1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C(2019 version)[J]. J Clin Hepatol,2019,35(12):2670-2686.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2670-2686.
    [2] di MAIO VC,CENTO V,ARAGRI M,et al. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures:What are the chances for second-line regimens?[J]. J Hepatol,2018,68(3):597-600.
    [3] SARRAZIN C,DVORY-SOBOL H,SVAROVSKAIA ES,et al.Prevalence of resistance-associated substitutions in HCV NS5A,NS5B,or NS3 and outcomes of treatment with ledipasvir and sofosbuvir[J]. Gastroenterology,2016,151(3):501-512. e1.
    [4] PAWLOTSKY JM. Hepatitis C drugs:Is next generation the last generation?[J]. Gastroenterology,2016,151(4):587-590.
    [5] BAUMERT TF,BERG T,LIM JK,et al. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges[J]. Gastroenterology,2019,156(2):431-445.
    [6] RAO HY,Directly acting antiviral agents in hepatitis C[J]. J Prac Hepatol,2016,19(4):390-393.(in Chinese)饶慧瑛．丙型肝炎直接抗病毒治疗研究进展[J]．实用肝脏病杂志，2016,19(4):390-393.
    [7] SARRAZIN C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice[J]. J Hepatol,2016,64(2):486-504.
    [8] PAWLOTSKY JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens[J]. Gastroenterology,2016,151(1):70-86.
    [9] ZHANG Y,CAO Y,ZHANG RW,et al. Natural resistance mutations to direct-acting antiviral agents in interferon/ribavirin treatment-experienced and treatment-naive patients with chronic hepatitis C in Beijing,China[J]. J Clin Hepatol,2016,32(4):711-715.(in Chinese)张玉，曹颖，张仁雯，等．北京地区干扰素联合利巴韦林经治与未经治慢性丙型肝炎患者直接抗病毒药物的天然耐药突变分析[J]．临床肝胆病杂志，2016,32(4):711-715.
    [10] CHEN Q,PERALES C,SORIA ME,et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure[J]. Antiviral Res,2020,174:104694.
    [11] CHEN JH,XU XY. Research of HCV variants resistant to direct-acting antiviral agents[J]. Infect Dis Info,2016,29(2):116-120.(in Chinese)陈建宏，徐小元．丙型肝炎直接抗病毒药物耐药相关变异的研究[J]．传染病信息，2016,29(2):116-120.
    [12] PARLATI L,POL S. Direct acting antivirals failure:Cause and retreatment options[J]. Expert Rev Gastroenterol Hepatol,2018,12(12):1245-1250.
    [13] CECCHERINI-SILBERSTEIN F,CENTO V,di MAIO VC,et al. Viral resistance in HCV infection[J]. Curr Opin Virol,2018,32:115-127.
    [14] di MAIO VC,CENTO V,LENCI I,et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies[J]. Liver Int,2017,37(4):514-528.
    [15] LONTOK E,HARRINGTON P,HOWE A,et al. Hepatitis C virus drug resistance-associated substitutions:State of the art summary[J]. Hepatology,2015,62(5):1623-1632.
    [16] WU R,GENG D,CHI X,et al. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3,NS5A,and NS5B among 86 subtypes of hepatitis C virus worldwide[J]. Infect Drug Resist,2019,12:2987-3015.
    [17] HAN B,MARTIN R,XU S,et al. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na6ve subjects[J]. Antiviral Res,2019,170:104574.
    [18] DIETZ J,SUSSER S,VERMEHREN J,et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals[J].Gastroenterology,2018,154(4):976-988. e4.
    [19] LIU Z,MAO X,YU K,et al. Prevalence of HCV resistanceassociated substitutions amongtreatment failurepatients receiving direct-acting antiviral agents[J]. J Viral Hepat,2020,27(6):585-592.
    [20] LIU Z,MAO X,WU J,et al. World-wide prevalence of substitutions in HCV genome associated with resistance to directacting antiviral agents[J]. Clin Gastroenterol Hepatol,2019.
    [21] WING P,JONES M,CHEUNG M,et al. Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir[J]. Gastroenterology,2019,157(3):692-704. e9.
    [22] HARRINGTON PR,KOMATSU TE,DEMING DJ,et al. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy:Regulatory analyses and perspectives[J].Hepatology,2018,67(6):2430-2448.
    [23] PEREZ AB,CHUECA N,GARCIA-DELTORO M,et al. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world[J]. J Hepatol,2019,71(5):876-888.
    [24] LAWITZ EJ,DVORY-SOBOL H,DOEHLE BP,et al. Clinical resistance to velpatasvir(GS-5816),a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein[J]. Antimicrob Agents Chemother,2016,60(9):5368-5378.
    [25] DVORY-SOBOL H,HAN B,LU J,et al. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6[J]. J Viral Hepat,2019,26(8):991-1001.
    [26] ESTEBAN R,PINEDA JA,CALLEJA JL,et al. Efficacy of sofosbuvir and velpatasvir,with and without ribavirin,in patients with hepatitis C virus genotype 3 infection and cirrhosis[J].Gastroenterology,2018,155(4):1120-1127. e4.
    [27] MCPHEE F. Developments in the treatment of HCV genotype 3 infection[J]. Expert Rev Anti Infect Ther,2019,17(10):775-785.
    [28] SEZAKI H,SUZUKI F,HOSAKA T,et al. Initial-and retreatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3infections[J]. J Gastroenterol,2019,54(10):916-927.
    [29] DIETZ J,SPENGLER U,MULLHAUPT B,et al. Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV genotype 1-3 infections[J]. Clin Gastroenterol Hepatol,2019.
    [30] OSAWA M,IMAMURA M,TERAOKA Y,et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures[J]. J Gastroenterol,2019,54(3):291-296.
    [31] GOTTWEIN JM,PHAM LV,MIKKELSEN LS,et al. Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7and escape variants[J]. Gastroenterology,2018,154(5):1435-1448.
    [32] KRISHNAN P,SCHNELL G,TRIPATHI R,et al. Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan[J]. Antimicrob Agents Chemother,2018,62(2).
    [33] SORBO MC,CENTOV,DI MAIO VC,et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance:Update 2018[J]. Drug Resist Updat,2018,37.
    [34] CHEN JH,ZENG Z,ZHANG XX,et al. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting[J]. World J Gastroenterol,2017,23(22):4072-4079.
    [35] BUTI M,ESTEBAN R. Management of direct antiviral agent failures[J]. Clin Mol Hepatol,2016,22(4):432-8.
    • Relative Articles

  • Relative Articles

    [1]Weiming DAI, Lungen LU, Xiaobo CAI. Association between liver sinusoidal endothelial cells and liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 419-423. doi: 10.3969/j.issn.1001-5256.2023.02.027
    [2]Yu ZHANG, Huali WANG, Shuming LU. Three cases of hepatic epithelioid hemangioendothelioma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2116-2119. doi: 10.3969/j.issn.1001-5256.2022.09.031
    [3]Hao XU, Bai RUAN, Zhiwen LI, Zhiqiang FANG, Lin WANG, Kefeng DOU. Establishment of a mouse model of vascular endothelial-mesenchymal transdifferentiation genetic tracing and its role in liver fibrosis studies[J]. Journal of Clinical Hepatology, 2022, 38(4): 832-836. doi: 10.3969/j.issn.1001-5256.2022.04.018
    [4]Jin XU, Yan PENG, Chuankang TANG. Value of neutrophil-lymphocyte ratio combined with apolipoprotein A-I level in predicting the severity of acute pancreatitis in the early stage after admission[J]. Journal of Clinical Hepatology, 2021, 37(3): 660-665. doi: 10.3969/j.issn.1001-5256.2021.03.030
    [5]Wei BiWei, Gong YaHui, Liang ZhiHai. Role of pyroptosis in the pathogenesis of acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1905-1908. doi: 10.3969/j.issn.1001-5256.2020.08.050
    [6]Qi QinQin, Yang Bin, Li HuiHui, Bao JunJun, Li HongYe, Wang BingBing, Mei Qiao. Level of platelet microparticles in acute pancreatitis and their role in the formation of neutrophil extracellular traps[J]. Journal of Clinical Hepatology, 2020, 36(4): 870-873. doi: 10.3969/j.issn.1001-5256.2020.04.032
    [7]Jiang Zhao, Ruan Bo. The role of liver sinusoidal endothelial cells in the progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 684-686. doi: 10.3969/j.issn.1001-5256.2020.03.047
    [8]Zhu ZiYi, Liu Yuan, Wang WenBo, Jiang ZhongYong, Chang Kai, Ye YuSheng, Xiong Jie. Mechanism of HCV stimulation of human umbilical vein endothelial cells in the pathogenesis of atherosclerosis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1313-1317. doi: 10.3969/j.issn.1001-5256.2019.06.026
    [9]Yu ZiYue, Lin Xin, Han Ying, Cui LiNa. Role of liver sinusoidal endothelial cells in liver regeneration and the development of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 2072-2074. doi: 10.3969/j.issn.1001-5256.2019.09.041
    [10]Wang Lin, Liu XueEn, Zhuang Hui. Cellular mechanisms in liver fibrosis regression[J]. Journal of Clinical Hepatology, 2018, 34(4): 862-866. doi: 10.3969/j.issn.1001-5256.2018.04.036
    [11]Zhu ZeMin, Xie ZhiQin, Zhao ZhiJian, Li HongXia, Xu Tao, Tang CaiXi. Pancreatic acinar cell carcinoma with acute pancreatitis as the first symptom: A case report[J]. Journal of Clinical Hepatology, 2018, 34(12): 2662-2664. doi: 10.3969/j.issn.1001-5256.2018.12.032
    [12]Hu QingMei, Niu ChunYan. Predictive value of combined measurement of D-dimer, fibrinogen, and peripheral blood leukocyte count for severity of acute pancreatitis[J]. Journal of Clinical Hepatology, 2017, 33(8): 1522-1526. doi: 10.3969/j.issn.1001-5256.2017.08.023
    [13]Wang Yan, Cui LiJian, Xiao HongLi, Wang GuoXing, Yin ChengHong. Effect of angiotensin 1-7 on the TLR4/NF-κB pathway in cerulein-induced pancreatic acinar cells[J]. Journal of Clinical Hepatology, 2016, 32(11): 2146-2150. doi: 10.3969/j.issn.1001-5256.2016.11.029
    [14]Jiao ShuHua, Liu PengLiang, Wen YanHui. Combined determination of serum C-reactive protein,lipase,interleukin-1β,and intercellular adhesion molecule1 in early identification of severity of acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(1): 131-134. doi: 10.3969/j.issn.1001-5256.2016.01.025
    [15]Hao TingTing, Ma XiaoPeng, Wen YanLi, Dai GuangRong, Feng YiChao, Zhang Li. Changes in serum levels of M30,M65,and IL-17 and their clinical significance in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 329-332. doi: 10.3969/j.issn.1001-5256.2016.02.027
    [16]Lu Wang, Zhang Rui, Jiang HongLi, Hu YuLin, Xin GuiJie. One case of hepatic epithelioid hemangioendothelioma[J]. Journal of Clinical Hepatology, 2015, 31(8): 1330-1331. doi: 10.3969/j.issn.1001-5256.2015.08.038
    [17]Wu Gang, Zheng Jie, Hu GuoXin, Peng YanZhong. Role of liver nonparenchymal cells in hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2014, 30(12): 1366-1369. doi: 10.3969/j.issn.1001-5256.2014.12.033
    [18]Ren LiNan, Guo XiaoZhong, Zou DeLi. EG-VEGF expression and significance in pancreatic carcinoma[J]. Journal of Clinical Hepatology, 2012, 28(8): 589-591.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(15)

    1. 许娟，闫涛涛，李严锋，侯静涛，樊研. ALBI评分联合PCT在肝硬化腹水患者自发性细菌性腹膜炎的预测作用. 胃肠病学和肝病学杂志. 2023(01): 85-89 .
    2. 周苏云，周影，程新月. 肝硬化患者发生肝性脑病的影响因素分析及对预检分诊意义的探讨. 中西医结合护理(中英文). 2023(03): 130-132 .
    3. 方翊天，吴若林，黄帆，王国斌，冯丽娟，余孝俊，侯刘进，叶征辉，耿小平，赵红川. 肝移植术后多重耐药菌感染危险因素的单中心临床研究. 器官移植. 2021(02): 197-202 .
    4. 李尚书，刘群，黄丽雯. 慢性肝病血小板减少的原因. 中国肝脏病杂志(电子版). 2021(02): 24-28 .
    5. 陆素芳，周红，王丹丹，陈益群，赵红利，张勇杨. MELD评分联合SII对失代偿期肝硬化患者预后的预测作用. 现代消化及介入诊疗. 2021(08): 973-977 .
    6. 黄敏，李冬冬，刘传苗. 乙肝相关慢加急性肝衰竭患者临床短期预后因素的分析. 中华全科医学. 2021(12): 2028-2030 .
    7. 贾亚男，李瀚，李先亮，贺强. 危重症肝病肝移植患者诊断和评估标准的临床进展. 器官移植. 2020(03): 326-331+368 .
    8. 姚运海，赵卫峰，甘建和. 苏州地区血吸虫性肝病患者临床特征及外周血T淋巴细胞亚群分布. 中国血吸虫病防治杂志. 2020(02): 154-158+167 .
    9. 张耀弟. △CTP评分评估肝硬化患者短期预后的价值分析. 甘肃科技. 2020(09): 117-118+152 .
    10. 刘小婷，杨欢，姚红，任小婵，罗选娟，王小闯. 碳青霉烯类耐药肺炎克雷伯菌感染死亡风险预测模型的建立及其对患者预后的预测价值研究. 中国全科医学. 2020(30): 3789-3797 .
    11. 韩志钧，韩柠泽，闫伟，马金彤. 肝血流动力学变化与肝储备功能相关性的研究. 中华医学超声杂志(电子版). 2020(06): 563-565 .
    12. 寇建涛，刘喆，朱继巧，马军，许文犁，李瀚，贾亚男，李先亮，贺强. 肝移植治疗危重症肝病的临床疗效研究. 器官移植. 2020(04): 482-486 .
    13. 宋梅，汪明星，李乐，何进伟，何丽丽. MELD评分结合降钙素原评估终末期肝病预后的临床分析. 中国医药科学. 2020(09): 254-256 .
    14. 李帆，成金英，刘贤贤，丁国锋. 乙肝肝硬化并发甲型流感及肺曲霉菌病1例并文献复习. 中国当代医药. 2020(34): 214-217 .
    15. 韩志钧，韩柠泽，闫伟，马金彤. 肝血流动力学变化与吲哚菁绿代谢试验评价肝储备功能的对比. 医学研究与教育. 2019(06): 28-31 .

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 24.8 %FULLTEXT: 24.8 %META: 69.6 %META: 69.6 %PDF: 5.5 %PDF: 5.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.3 %其他: 8.3 %其他: 1.6 %其他: 1.6 %China: 0.8 %China: 0.8 %Russian Federation: 0.3 %Russian Federation: 0.3 %[]: 0.5 %[]: 0.5 %三亚: 0.2 %三亚: 0.2 %上海: 1.8 %上海: 1.8 %中卫: 0.2 %中卫: 0.2 %佛山: 0.2 %佛山: 0.2 %兰州: 0.3 %兰州: 0.3 %北京: 4.4 %北京: 4.4 %南京: 1.3 %南京: 1.3 %南宁: 0.3 %南宁: 0.3 %南阳: 0.2 %南阳: 0.2 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %台州: 0.2 %台州: 0.2 %合肥: 1.5 %合肥: 1.5 %吉林: 0.5 %吉林: 0.5 %呼和浩特: 0.3 %呼和浩特: 0.3 %唐山: 0.2 %唐山: 0.2 %商丘: 0.2 %商丘: 0.2 %大连: 0.2 %大连: 0.2 %天津: 0.2 %天津: 0.2 %太原: 0.2 %太原: 0.2 %宁波: 0.2 %宁波: 0.2 %安康: 0.2 %安康: 0.2 %安阳: 0.2 %安阳: 0.2 %宣城: 0.3 %宣城: 0.3 %密蘇里城: 1.1 %密蘇里城: 1.1 %巴黎: 0.5 %巴黎: 0.5 %常德: 0.2 %常德: 0.2 %广州: 0.3 %广州: 0.3 %张家口: 4.4 %张家口: 4.4 %德罕: 0.2 %德罕: 0.2 %成都: 0.5 %成都: 0.5 %扬州: 0.2 %扬州: 0.2 %拉斯维加斯: 0.5 %拉斯维加斯: 0.5 %昆明: 0.2 %昆明: 0.2 %杭州: 0.2 %杭州: 0.2 %武汉: 1.1 %武汉: 1.1 %洛阳: 0.3 %洛阳: 0.3 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.5 %海得拉巴: 0.5 %湖州: 0.2 %湖州: 0.2 %湘潭: 0.2 %湘潭: 0.2 %湛江: 0.2 %湛江: 0.2 %漯河: 0.2 %漯河: 0.2 %福州: 0.2 %福州: 0.2 %罗奥尔凯埃: 0.2 %罗奥尔凯埃: 0.2 %自贡: 0.2 %自贡: 0.2 %芒廷维尤: 43.0 %芒廷维尤: 43.0 %芝加哥: 0.5 %芝加哥: 0.5 %苏州: 0.2 %苏州: 0.2 %茂名: 0.2 %茂名: 0.2 %莫斯科: 3.6 %莫斯科: 3.6 %西宁: 10.4 %西宁: 10.4 %诺沃克: 0.6 %诺沃克: 0.6 %贵阳: 0.2 %贵阳: 0.2 %运城: 2.3 %运城: 2.3 %金华: 0.3 %金华: 0.3 %长春: 1.8 %长春: 1.8 %长沙: 0.5 %长沙: 0.5 %长治: 0.2 %长治: 0.2 %马湾: 0.2 %马湾: 0.2 %马鞍山: 0.2 %马鞍山: 0.2 %黔西南: 0.2 %黔西南: 0.2 %其他其他ChinaRussian Federation[]三亚上海中卫佛山兰州北京南京南宁南阳卡纳塔克台州合肥吉林呼和浩特唐山商丘大连天津太原宁波安康安阳宣城密蘇里城巴黎常德广州张家口德罕成都扬州拉斯维加斯昆明杭州武汉洛阳济南海得拉巴湖州湘潭湛江漯河福州罗奥尔凯埃自贡芒廷维尤芝加哥苏州茂名莫斯科西宁诺沃克贵阳运城金华长春长沙长治马湾马鞍山黔西南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (619) PDF downloads(84) Cited by(16)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3692]YesterdayPV[7162]TodayIP[4992]TodayPV[10586]Online[251]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return